BioNTech’s (BNTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $107.00 price objective on the stock.

Several other brokerages have also recently issued reports on BNTX. Oppenheimer assumed coverage on shares of BioNTech in a report on Friday, January 5th. They issued a market perform rating on the stock. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $99.00 to $90.00 and set an underweight rating on the stock in a research report on Friday, March 22nd. The Goldman Sachs Group lowered their price objective on shares of BioNTech from $113.00 to $100.00 and set a neutral rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group reissued a buy rating and issued a $171.00 target price on shares of BioNTech in a research note on Thursday, March 21st. Finally, UBS Group dropped their price objective on BioNTech from $110.00 to $101.00 and set a neutral rating for the company in a report on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and an average target price of $120.40.

BioNTech Trading Up 0.1 %

Shares of BNTX opened at $86.40 on Wednesday. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83. The stock has a market cap of $20.54 billion, a PE ratio of 20.97 and a beta of 0.23. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $91.49 and its 200-day moving average price is $97.57.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. On average, equities analysts forecast that BioNTech will post -1.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. Captrust Financial Advisors raised its holdings in BioNTech by 6.9% in the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company’s stock worth $159,000 after purchasing an additional 69 shares in the last quarter. Centaurus Financial Inc. increased its stake in shares of BioNTech by 5.2% in the 1st quarter. Centaurus Financial Inc. now owns 1,448 shares of the company’s stock worth $247,000 after acquiring an additional 71 shares in the last quarter. Pathstone Family Office LLC lifted its position in BioNTech by 4.9% during the 4th quarter. Pathstone Family Office LLC now owns 2,205 shares of the company’s stock valued at $331,000 after acquiring an additional 103 shares during the period. Cary Street Partners Investment Advisory LLC boosted its stake in BioNTech by 6.9% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock worth $186,000 after acquiring an additional 111 shares in the last quarter. Finally, Sectoral Asset Management Inc. grew its holdings in BioNTech by 3.5% in the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock worth $374,000 after purchasing an additional 116 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.